Coventry Terminates Deal with Sequenom; Further Data Published on MaterniT21 Plus Test | GenomeWeb

NEW YORK (GenomeWeb News) – Coventry Health Care National Network has terminated its coverage agreement with Sequenom covering the MaterniT21 Plus test, just one week after the agreement was announced, the San Diego-based molecular diagnostics firm said after the close of the market on Thursday.

Coventry told Sequenom that the termination was without cause and was not a judgment on Sequenom, its Sequenom Center for Molecular Medicine subsidiary — which administers the non-invasive test for fetal aneuploidies — or its products, Sequenom said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.

A man is using DNA evidence to argue that he is the rightful heir to the baronetcy of Stichill, the Guardian reports.

As part of an effort to get a diverse group of people to donate their DNA for research, some blood donors in the San Diego area will get their genomes sequenced, according to KPBS.

The comment period on the Department of Health and Human Services' proposal to alter the Common Rule has been extended.